Amicus Therapeutics

Bradley Campbell, President and Chief Operating Officer
Cranbury, NJ
Amicus Therapeutics is a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering novel high quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. The Company’s portfolio of product opportunities is led by a novel medicine for Fabry disease, Galafold®, that has achieved widespread global approval, a differentiated biologic, AT-GAA, for Pompe disease in the clinic, and an industry-leading rare disease gene therapy portfolio.

By using this website you agree to accept our Privacy Policy and Terms & Conditions